Hunan Jingfeng Pharmaceutical Co.,Ltd.

Symbol: 000908.SZ

SHZ

2.07

CNY

Market price today

  • -11.5941

    P/E Ratio

  • -0.1406

    PEG Ratio

  • 1.82B

    MRK Cap

  • 0.00%

    DIV Yield

Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ). Companys revenue shows the average of 690.609 M which is 0.491 % gowth. The average gross profit for the whole period is 459.59 M which is 2.233 %. The average gross profit ratio is 0.387 %. The net income growth for the company last year performance is -0.500 % which equals 1.939 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Hunan Jingfeng Pharmaceutical Co.,Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.181. In the realm of current assets, 000908.SZ clocks in at 571.297 in the reporting currency. A significant portion of these assets, precisely 181.392, is held in cash and short-term investments. This segment shows a change of 0.054% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 50.456, if any, in the reporting currency. This indicates a difference of -54.662% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 82.36 in the reporting currency. This figure signifies a year_over_year change of -0.314%. Shareholder value, as depicted by the total shareholder equity, is valued at 177.928 in the reporting currency. The year over year change in this aspect is -0.419%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 233.178, with an inventory valuation of 120.37, and goodwill valued at 33.03, if any. The total intangible assets, if present, are valued at 204.36. Account payables and short-term debt are 138.54 and 516.45, respectively. The total debt is 598.81, with a net debt of 417.42. Other current liabilities amount to 402.16, adding to the total liabilities of 1253.65. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

balance-sheet.row.cash-and-short-term-investments

699.02181.4172.2164.2
405.5
512.1
472.1
1201.9
519.7
214.5
33.4
18.6
16.6
47.3
32.8
53.3
93.9
15.4
65.5
154.1
302
266
174.2
210.5
334.4
291.2
7.9
16.4
6.1

balance-sheet.row.short-term-investments

-4.440-7.4-103.6
-137.8
343.6
-81.5
-30.5
0
0
0
0
0
0
2.4
-67
0.8
0.3
29.7
54.8
165.3
1.6
0
60
60
50
0
0
0

balance-sheet.row.net-receivables

964.55233.2301.3575.9
877.9
1786.3
1828.1
1742.8
1251
866.6
99.9
108.8
162.9
195.6
205.2
248.2
379.6
261.2
591.2
603.2
324.8
183.4
146.4
53.5
11.1
71.8
47.5
43.8
13.1

balance-sheet.row.inventory

420.12120.4155.4232.4
326.3
268.9
276.1
236.2
160.9
128.6
33.2
41.3
38.5
35.5
31
102.6
71.2
95.6
98.8
90.7
77.9
113.3
92.7
59.8
38.7
19.1
18.6
25.4
17.3

balance-sheet.row.other-current-assets

146.3736.448.749.4
173.9
23.1
5.2
16.8
1.9
-138.6
-6.1
-10.3
-15.6
-30.9
-36.6
-44.7
-120.1
0
-221.4
-216.8
0
-27.8
-20.5
130.6
107.1
-21.7
-8.6
-11.4
-2.8

balance-sheet.row.total-current-assets

2230.06571.3677.51021.9
1783.6
2590.4
2581.6
3197.8
1933.6
1071.2
160.5
158.4
202.4
247.6
232.3
359.3
424.5
372.2
534.1
631.2
704.7
534.9
392.8
454.4
491.3
360.5
65.4
74.3
33.6

balance-sheet.row.property-plant-equipment-net

2189.93566.4726.11013.8
1232
1049.2
785
667.7
483.9
347.4
83.7
104.2
109.2
104.4
122.5
131
115.7
174.6
180.2
146.3
155
189.2
158.4
115.1
81.7
65
38.6
40.9
24.7

balance-sheet.row.goodwill

132.12333372
432.7
737.4
705.8
705.8
688.3
355.9
208.6
0
0
0
0
0
0.4
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

913.89204.4210.4244.8
365.2
348.2
248.5
162.4
70.9
29.6
43.8
58.6
58.6
45.5
321.1
356.1
83.3
105.4
92.2
91.8
103.1
109.1
41.4
49.1
43.8
24
11
4.4
3.1

balance-sheet.row.goodwill-and-intangible-assets

1046.01237.4243.5316.8
797.9
1085.6
954.3
868.2
759.2
385.5
43.8
58.6
58.6
45.5
321.1
356.1
83.7
105.4
92.2
91.8
103.1
109.1
41.4
49.1
43.8
24
11
4.4
3.1

balance-sheet.row.long-term-investments

21950.5111.3270.4
456.5
0
421.8
251.1
0
0
0
0
0
0
46.3
121.6
114.6
169.3
3.3
-35.2
-146.4
29.7
0
-34.9
-37.3
-26.6
0
0
0

balance-sheet.row.tax-assets

103.8127.923.664.3
57.2
48
17.1
19.2
20.5
13.6
0
0
0
0.8
1
7.2
7.1
0
0
0
0
0
0
61.1
60.3
50
0
0
0

balance-sheet.row.other-non-current-assets

50.811510.42.9
22.9
453.9
109
130
245.4
96.1
48.8
48.8
51.3
73.1
61.5
14
68.7
0.9
30.4
55.4
166.6
3.8
28.2
53.1
52.1
0.3
17.2
12
4.8

balance-sheet.row.total-non-current-assets

3609.56897.21114.81668.1
2566.4
2636.7
2287.2
1936.3
1509.1
842.6
176.3
211.7
219
223.8
552.5
629.9
389.9
450.2
306
258.4
278.3
331.7
228
243.5
200.6
112.7
66.8
57.2
32.7

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

5839.621468.51792.32690
4350.1
5227.1
4868.8
5134
3442.6
1913.8
336.8
370.1
421.4
471.4
784.8
989.2
814.4
822.5
840.1
889.6
983
866.7
620.9
697.9
691.9
473.2
132.2
131.5
66.3

balance-sheet.row.account-payables

511.16138.5123186.2
187.1
194.8
114.2
111
134.5
86.7
58.2
61.4
46.4
50
45.6
49.9
53.3
54
62.8
110.1
181.9
79.2
46.5
34.6
16.4
11.2
9.6
7.6
5.4

balance-sheet.row.short-term-debt

2036.35516.5864.61423.1
1306.5
895.3
621.2
809.4
516.5
480
233.6
296.1
327.8
219
226
367
405.4
358.7
377.1
369.6
340.6
225.1
37.6
81.9
125.3
5
1.1
9
4.4

balance-sheet.row.tax-payables

142.754724.87.6
8.9
106.7
109.8
152.4
114.1
61.3
-18.4
-20
-21.3
-24.3
-27.8
-35.4
-19.5
-10.3
-16.2
-21.2
-12.5
-5.3
-2.3
8
8.6
7
1.5
0.5
-0.4

balance-sheet.row.long-term-debt-total

329.8282.48.937.8
389
874.3
1182.8
1169.9
160.8
56
-74.7
0
0
114.8
144.8
192.1
0
0
0
10
0
10
24.4
42.7
40.2
27.2
19.3
11
10

Deferred Revenue Non Current

92.1824.851124.2
173.2
61.6
37.2
38.8
39.7
39
29.7
0
0
-114.8
192.1
0
0
0
0
0
0
0
0
-42.7
-40.2
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

18.31---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

822.32402.22.32.8
49.2
186.3
53.6
32.6
24.9
10.5
3.7
8.6
3.9
4.7
16.1
12.6
5.7
7.9
11.3
35.6
29.6
19.3
7
6.7
4.9
3
2.7
3.7
2.9

balance-sheet.row.total-non-current-liabilities

674.69170.3103.5193.2
739.9
981.9
1221.4
1229
224.6
121.9
3.9
4
5.4
119.1
352.2
200.3
6.3
0
0
17
6
10
24.4
46.8
45.7
34.2
19.3
11
10

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

39.599.87.945.6
152.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

4992.991253.61464.62051.8
2408.3
2365
2268.9
2521.6
1194.2
919.8
331.5
430.3
420.7
413.5
684.1
650.6
477.4
486.1
510.5
550.1
563.6
344
122.5
197.4
206.5
72.5
45.7
70.7
35.5

balance-sheet.row.preferred-stock

306.2900135.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

1666.76416.7416.7416.7
416.7
416.7
416.7
416.7
336.7
275.4
280
280
280
280
280
280
280
280
280
280
280
280
280
280
140
140
0
0
0

balance-sheet.row.retained-earnings

-3856.4-949-820.9-657.2
413.4
1296.2
1122.8
982.9
739
466.6
-472.4
-475.7
-414.9
-358
-361
-122.5
-89
-91.9
-94.6
-97.6
-21.3
89.8
77.9
75.3
73.7
28.1
3.8
0
0

balance-sheet.row.accumulated-other-comprehensive-income-loss

1824.35710.3710.6-135.5
757.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

710.6400760.5
0
770.7
839
992.6
1097.9
239.2
197.3
135.3
135.3
135.3
134.6
134.2
142.8
146.7
142.8
142.6
141.9
141.4
139.6
135.4
240.5
232.5
82.8
0
0

balance-sheet.row.total-stockholders-equity

651.64177.9306.4520
1588
2483.7
2378.5
2392.2
2173.7
981.2
4.9
-60.5
0.3
57.3
53.7
291.7
333.8
334.8
328.2
325
400.5
511.2
497.5
490.7
454.3
400.6
86.5
60.8
30.8

balance-sheet.row.total-liabilities-and-stockholders-equity

5839.621468.51792.32690
4350.1
5227.1
4868.8
5134
3442.6
1913.8
336.8
370.1
421.4
471.4
784.8
989.2
814.4
822.5
840.1
889.6
983
866.7
620.9
697.9
691.9
473.2
132.2
131.5
66.3

balance-sheet.row.minority-interest

194.9936.921.3118.1
353.8
378.4
221.4
220.2
74.8
12.8
0.4
0.3
0.5
0.6
47
47
3.1
1.6
1.5
14.5
18.8
11.5
0.9
9.8
31.1
0
0
0
0

balance-sheet.row.total-equity

846.63214.8327.7638.2
1941.8
2862.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

5839.62---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

214.5550.5103.9166.8
318.8
343.6
340.3
220.6
235.9
86.4
45.6
45.7
48.6
48.6
48.7
54.6
115.4
169.7
32.9
19.7
18.8
31.3
25.7
25.1
22.7
23.4
16.7
11.2
3.8

balance-sheet.row.total-debt

2366.17598.8873.51423.1
1695.5
1769.6
1804
1979.2
677.3
536
233.6
296.1
327.8
333.8
370.8
367
405.4
358.7
377.1
379.6
340.6
235.1
62.1
124.6
165.5
32.2
20.5
20
14.4

balance-sheet.row.net-debt

1667.15417.4701.31258.9
1290
1257.5
1331.9
777.3
157.5
321.5
200.1
277.5
311.2
286.5
340.4
313.7
312.3
343.6
341.2
280.3
203.8
-29.4
-112.2
-25.9
-109
-209.1
12.5
3.6
8.3

Cash Flow Statement

The financial landscape of Hunan Jingfeng Pharmaceutical Co.,Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.280. The company recently extended its share capital by issuing 0, marking a difference of 0.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to 221731090.000 in the reporting currency. This is a shift of -0.187 from the previous year. In the same period, the company recorded 55.41, 118.33, and -454.23, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -39.63 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 157.68, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

-128.24-100.9-201.6-1047.7
-921.6
198.5
185.2
388.1
370.2
257.4
3.4
-60.9
-57.1
2.9
-244
-31.9
5.8
2.7
3
-65.3
14.7
14.4
11.9
46.3
56.8
29.3

cash-flows.row.depreciation-and-amortization

1255.4107.581.5
76.4
92.6
73.4
60.4
41.7
27.5
8.3
8.8
9.1
9.8
19.1
15.7
11.1
11.9
10.7
10.4
12.5
9.9
6.9
5.6
4.4
0

cash-flows.row.deferred-income-tax

000-6.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0006.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

92.272.5321.9158.5
498.9
-53.1
-222.5
-517.7
-384.8
-118.4
-5.9
15.2
20.2
-59.2
43.3
27.7
38.8
13.4
-95.6
-159.4
-19
-13.1
20.1
-70.3
-32.2
0

cash-flows.row.account-receivables

54.9254.9254.9274
449.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

37.2837.369.482.4
-58.7
7.9
-39.9
9.8
-9.1
-10.4
6.5
-7.2
-4.2
-4.6
49.9
-32.2
24.4
3.3
-24.1
-16.1
-21.5
-16
-32.9
-21.1
-17.6
0

cash-flows.row.account-payables

0-54.9-254.9-191.9
-449.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

035.2252.6-5.9
557.6
-61
-182.7
-527.5
-375.7
-108
-12.4
22.4
24.4
-54.6
-6.6
60
14.4
10.2
-71.5
-143.3
2.5
2.8
53
-49.2
-14.5
0

cash-flows.row.other-non-cash-items

-41.8696.2-103.9536
382.4
112.9
115.5
81.5
65.2
39.4
-9.3
37.3
20.9
31.2
169.7
19.6
-3.4
29.8
22.4
57.8
14.3
6.4
-8.3
-6.6
-15.4
-29.3

cash-flows.row.net-cash-provided-by-operating-activities

-65.89000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-16.67-13.5-38.1-96
-113.6
-171.1
-303.2
-252.8
-223.2
-100.6
-1.7
-5.2
-4.8
-3.9
-11.8
-26.9
-0.6
-0.6
-1.3
-5.5
-15.2
-99.8
-41.5
-45.6
-18.3
-4.1

cash-flows.row.acquisitions-net

-8.863.6253.4434.2
135.6
-10.1
-317.3
-243.3
-532.7
-321.1
0.7
0
10.1
42.2
12.3
0.1
0.1
1.8
1.3
10.7
2
0
41.5
0.2
0.2
0

cash-flows.row.purchases-of-investments

000-250
-322
-120
303.3
-106
0
0
0
-0.8
0
-0.3
-8.8
-14.2
-31.3
-34.8
-6
-37.3
-0.1
-7
-6.9
-122.4
-112
-50.4

cash-flows.row.sales-maturities-of-investments

0.0353.345.4352.6
231.8
100.6
15.4
102
10.2
0
0
0
0
30.3
14.1
35.8
1.5
3.2
8.2
139
7
5.6
122.1
137.1
58.6
0

cash-flows.row.other-investing-activites

120.56118.3122
17.4
0.8
-303.2
24
9.3
-15.3
5.2
36.8
0.1
0
-11.8
0.5
1.5
-0.6
-1.3
3.7
-4.2
0.1
-41.5
-24.9
-38.7
0.1

cash-flows.row.net-cash-used-for-investing-activites

95.11221.7272.7442.7
-50.8
-199.7
-605.1
-476.2
-736.4
-437
4.2
30.8
5.3
68.3
-5.9
-4.7
-28.7
-31
0.9
110.5
-10.4
-101.1
73.7
-55.5
-110.2
-54.5

cash-flows.row.debt-repayment

-294.2-454.2-585.3-1214.9
-1252.4
-820.2
-918.8
-803.5
-588.2
-236.3
-131.9
-36.7
-6
-214.9
-61
-188.8
-256.1
-292.2
-205.1
-325
-232.5
-112.6
-136.3
-135.9
-22
-0.6

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-21.47-39.6-91.5-89.2
-86.6
-102.1
-91.4
-132.2
-51.8
-28.7
-53
0
-3.8
-8.1
-16.5
-19.9
-23.4
-29.9
-23.3
-31.1
-16.4
-9.1
-17.2
-8.6
-2.8
-3.2

cash-flows.row.other-financing-activites

166.04157.7289.5889.4
1245
809.8
735.3
2080.1
1589.2
564.9
193.9
5
0
173.9
64.8
142.6
334
274.5
226.1
364.5
186.5
295.4
73.8
101.2
154.6
265.2

cash-flows.row.net-cash-used-provided-by-financing-activities

-156.83-336.2-387.3-414.7
-94
-112.6
-274.9
1144.4
949.3
299.8
9
-31.7
-9.8
-49.1
-12.7
-66.1
54.5
-47.6
-2.3
8.4
-62.4
173.7
-79.7
-43.4
129.7
261.4

cash-flows.row.effect-of-forex-changes-on-cash

0.150.2-0.1-2
2
1.3
-1.4
1.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-11.7199.2-245.7
-106.6
40
-729.8
682.2
305.2
68.8
9.8
-0.6
-11.4
4
-30.5
-39.8
78
-20.7
-60.9
-37.5
-50.3
90.2
24.5
-123.9
33.2
206.9

cash-flows.row.cash-at-end-of-period

695.54177.9168.9159.8
405.5
512.1
472.1
1201.9
519.7
214.5
24.6
14.8
15.4
26.8
22.8
53.3
93.1
15.1
35.8
99.3
214.1
264.4
174.2
150.5
274.4
206.9

cash-flows.row.cash-at-beginning-of-period

707.25168.9159.8405.5
512.1
472.1
1201.9
519.7
214.5
145.7
14.8
15.4
26.8
22.8
53.3
93.1
15.1
35.8
96.8
136.7
264.4
174.2
149.7
274.4
241.3
0

cash-flows.row.operating-cash-flow

-65.89123.3123.8-271.7
36.2
350.9
151.7
12.3
92.4
205.9
-3.4
0.4
-6.9
-15.2
-11.9
31
52.3
57.9
-59.5
-156.4
22.5
17.6
30.5
-25
13.6
0

cash-flows.row.capital-expenditure

-16.67-13.5-38.1-96
-113.6
-171.1
-303.2
-252.8
-223.2
-100.6
-1.7
-5.2
-4.8
-3.9
-11.8
-26.9
-0.6
-0.6
-1.3
-5.5
-15.2
-99.8
-41.5
-45.6
-18.3
-4.1

cash-flows.row.free-cash-flow

-82.56109.885.7-367.7
-77.5
179.8
-151.6
-240.5
-130.8
105.3
-5.2
-4.8
-11.7
-19.1
-23.6
4.1
51.7
57.3
-60.8
-161.9
7.4
-82.2
-11
-70.7
-4.6
-4.1

Income Statement Row

Hunan Jingfeng Pharmaceutical Co.,Ltd.'s revenue saw a change of 0.036% compared with the previous period. The gross profit of 000908.SZ is reported to be 640.99. The company's operating expenses are 624.14, showing a change of -18.030% from the last year. The expenses for depreciation and amortization are 55.41, which is a -0.484% change from the last accounting period. Operating expenses are reported to be 624.14, which shows a -18.030% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 1.674% year-over-year growth. The operating income is 14.47, which shows a -1.674% change when compared to the previous year. The change in the net income is -0.500%. The net income for the last year was -100.89.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

income-statement-row.row.total-revenue

782.67840.7811.2877.9
1344
2585.7
2583.7
2640.5
2459
1957.4
167.3
145.3
139
217.4
236.4
216.8
187.7
237.6
214.4
258.6
217.1
214.4
171.2
189.3
136
86.4
65.9
68.6
67.5

income-statement-row.row.cost-of-revenue

198.72199.7308318.4
537.1
629.4
552.3
559.3
463.5
289.1
131.6
122
118.7
181.1
242.1
186.5
161.2
170.2
160.9
232.7
204.7
165.6
138
133.6
82.4
48
37
46.3
49.3

income-statement-row.row.gross-profit

583.95641503.2559.5
807
1956.3
2031.3
2081.2
1995.5
1668.3
35.7
23.3
20.3
36.3
-5.7
30.3
26.5
67.4
53.5
25.9
12.4
48.8
33.2
55.7
53.6
38.4
28.9
22.3
18.2

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

30.31---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

60.45---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

393.67---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

109.54107.3129.4142.2
168.5
-11.2
-8.3
30.7
18.1
13.1
2.1
0.9
18.4
27
-7.3
3.1
5.9
2
1.7
1.8
-8
5.7
4.1
6.5
2.3
1
1.6
2.2
0.8

income-statement-row.row.operating-expenses

594.53624.1761.41074
1362.2
1604.2
1678.8
1570.8
1524
1338.9
42.9
47.9
54.8
46.8
61.5
45.9
30.5
36.6
31.3
62.2
42.4
34.6
34.1
20.3
12.7
10.1
6.1
8.9
8.1

income-statement-row.row.cost-and-expenses

793.25823.81069.41392.4
1899.3
2233.6
2231.2
2130.1
1987.5
1628
174.5
169.9
173.6
227.8
303.5
232.4
191.8
206.8
192.2
294.9
247.1
200.2
172.1
153.8
95.1
58.1
43.1
55.2
57.4

income-statement-row.row.interest-income

0.81.10.61.4
6.7
2.2
3.7
2.7
2.6
0.8
0.3
0.1
0.3
0.6
0.6
1.4
1.8
1.2
1.2
2.8
4.7
1.8
2.7
3.9
0
0
0
0
0

income-statement-row.row.interest-expense

43.1452.486.1106.2
105
84.6
93.5
68.4
49.8
28.5
6.1
20.4
19.8
19.9
30.9
28.9
24.7
29.9
21.8
23.2
16.3
9.3
7.4
8.6
-1.5
2.1
2.4
2.5
3

income-statement-row.row.selling-and-marketing-expenses

393.67---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-12.07-105-134-637.4
-364.5
-108.4
-102.7
-39.8
-37.8
-23.4
10.5
-36.5
-21.8
13.5
-170.8
-16.6
8.8
-28.7
-19.3
-27.8
-21.5
-1.8
8.4
13.6
23.5
4.3
4.2
6
-2.1

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

109.54107.3129.4142.2
168.5
-11.2
-8.3
30.7
18.1
13.1
2.1
0.9
18.4
27
-7.3
3.1
5.9
2
1.7
1.8
-8
5.7
4.1
6.5
2.3
1
1.6
2.2
0.8

income-statement-row.row.total-operating-expenses

-12.07-105-134-637.4
-364.5
-108.4
-102.7
-39.8
-37.8
-23.4
10.5
-36.5
-21.8
13.5
-170.8
-16.6
8.8
-28.7
-19.3
-27.8
-21.5
-1.8
8.4
13.6
23.5
4.3
4.2
6
-2.1

income-statement-row.row.interest-expense

43.1452.486.1106.2
105
84.6
93.5
68.4
49.8
28.5
6.1
20.4
19.8
19.9
30.9
28.9
24.7
29.9
21.8
23.2
16.3
9.3
7.4
8.6
-1.5
2.1
2.4
2.5
3

income-statement-row.row.depreciation-and-amortization

89.8655.4107.5276.4
138
92.6
73.4
60.4
41.7
27.5
8.3
8.8
9.1
9.8
19.1
15.7
11.1
11.9
10.7
10.4
12.5
9.9
6.9
5.6
4.4
-5
-4.9
-6.1
0.9

income-statement-row.row.ebitda-caps

-6.4---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-96.2614.5-21.5-514.5
-555.3
254.9
258.1
440.9
415.8
293.6
2.5
-61.9
-55.2
-24
-230.6
-35
-1.1
1.6
2.7
-67.2
-50.9
16.3
12.2
52.8
64
33.3
27.7
19.5
9.2

income-statement-row.row.income-before-tax

-108.33-90.6-155.4-1151.9
-919.8
243.8
249.8
470.6
433.7
306.1
3.3
-61.1
-56.4
3
-238
-32.1
4.8
2.9
3.7
-64.8
-50.2
17.2
11.9
54.1
65.3
33.4
28.1
20.5
9

income-statement-row.row.income-tax-expense

6.110.346.23.4
1.8
45.2
64.6
82.5
63.5
48.7
-0.1
-0.1
0.7
0.1
6.1
-0.2
-1
0.2
0.7
0.5
2.1
3.1
0.9
7.8
8.5
4.1
1.3
1.9
1

income-statement-row.row.net-income

-128.24-100.9-201.6-1155.3
-921.6
186.8
162.1
340
324.1
251
3.4
-60.8
-57
3
-238.4
-33.5
5.7
2.7
3
-65.1
-52.8
14
12.2
46.2
56.8
29.3
26.9
18.7
8

Frequently Asked Question

What is Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ) total assets?

Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ) total assets is 1468474402.000.

What is enterprise annual revenue?

The annual revenue is 377777673.000.

What is firm profit margin?

Firm profit margin is 0.746.

What is company free cash flow?

The free cash flow is -0.094.

What is enterprise net profit margin?

The net profit margin is -0.164.

What is firm total revenue?

The total revenue is -0.123.

What is Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ) net profit (net income)?

The net profit (net income) is -100887165.530.

What is firm total debt?

The total debt is 598814804.000.

What is operating expences number?

The operating expences are 624136704.000.

What is company cash figure?

Enretprise cash is 174649910.000.